Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: Results of the ring studies of the international immuno-oncology biomarker working group

Modern Pathology

Volumn 29, Issue 10, 2016, Pages 1155-1164

  Denkert, Carsten ^a,b   Wienert, Stephan ^a,c   Poterie, Audrey ^d   Loibl, Sibylle ^e,f   Budczies, Jan ^a,b   Badve, Sunil ^g   Bago Horvath, Zsuzsanna ^h   Bane, Anita ⁱ   Bedri, Shahinaz ^j   Brock, Jane ^k   Chmielik, Ewa ^l   Christgen, Matthias ^m   Colpaert, Cecile ⁿ   Demaria, Sandra ^o   Van Den Eynden, Gert ⁿ   Floris, Giuseppe ^p   Fox, Stephen B ^q   Gao, Dongxia ^r   Ingold Heppner, Barbara ^a   Kim, S Rim ^s   Kos, Zuzana ^t   Kreipe, Hans H ^m   Lakhani, Sunil R ^u   Penault Llorca, Frederique ^v   Pruneri, Giancarlo ^w   Radosevic Robin, Nina ^v   Rimm, David L ^x   Schnitt, Stuart J ^y   Sinn, Bruno V ^a,z   Sinn, Peter ^aa   Sirtaine, Nicolas ^ab   O'Toole, Sandra A ^ac   Viale, Giuseppe ^w   Van De Vijver, Koen ^ad   De Wind, Roland ^ab   Von Minckwitz, Gunter ^e   Klauschen, Frederick ^a   Untch, Michael ^ae   Fasching, Peter A ^af   Reimer, Toralf ^ag   Willard Gallo, Karen ^ab   Michiels, Stefan ^ah   Loi, Sherene ^q   Salgado, Roberto ^n,ab   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c VMSCOPE GMBH   (Germany)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e German Breast Group (GBG Forschungs GmbH)   (Germany)

^f SANA KLINIKUM OFFENBACH   (Germany)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^k HARVARD MEDICAL SCHOOL   (United States)

^l INSTITUTE OF ONCOLOGY   (Poland)

^m HANNOVER MEDICAL SCHOOL   (Germany)

ⁿ GZA Ziekenhuizen ^*  (Belgium)

^o WEILL CORNELL MEDICAL COLLEGE   (United States)

^p UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^q PETER MACCALLUM CANCER CENTRE   (Australia)

^r VANCOUVER GENERAL HOSPITAL   (Canada)

^s NSABP Foundation Inc   (United States)

^t UNIVERSITY OF OTTAWA   (Canada)

^u UNIVERSITY OF QUEENSLAND   (Australia)

^v UNIVERSITÉ CLERMONT AUVERGNE   (France)

^w UNIVERSITY OF MILAN   (Italy)

^x YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^y BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^z UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^aa UNIVERSITY OF HEIDELBERG   (Germany)

^ab JULES BORDET INSTITUTE   (Belgium)

^ac ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^ad NETHERLANDS CANCER INSTITUTE   (Netherlands)

^ae HELIOS KLINIKUM BERLIN BUCH   (Germany)

^af UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^ag Klinikum Sudstadt Rostock   (Germany)

^ah CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CORRELATION COEFFICIENT; HUMAN; IMMUNOLOGICAL PARAMETERS; MEDICAL SOCIETY; PATHOLOGIST; PRIORITY JOURNAL; SOFTWARE; STANDARDIZATION; TUMOR ASSOCIATED LEUKOCYTE; BREAST TUMOR; COMPUTER ASSISTED DIAGNOSIS; FEMALE; IMMUNOLOGY; PATHOLOGY; PROCEDURES; STANDARDS;

BREAST NEOPLASMS; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LYMPHOCYTES, TUMOR-INFILTRATING; PATHOLOGY, CLINICAL;

EID: 84976592728     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.109     Document Type: Article

References (20)

1. Fridman WH, Pagès F, Sautès-Fridman C et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298-306.
2. Disis ML. Immune regulation of cancer. J Clin Oncol 2010;28:4531-4538.
3. Ignatiadis M, Singhal SK, Desmedt C et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012;30:1996-2004.
4. Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 2014;15:e58-e68.
5. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:105-113.
6. Issa-Nummer Y, Darb-Esfahani S, Loibl S et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer-a substudy of the neoadjuvant GeparQuinto trial. PLoS One 2013;8:e79775.
7. Denkert C, von Minckwitz G, Brase JC et al. Tumorinfiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triplenegative primary breast cancers. J Clin Oncol 2015;33: 983-991.
8. West NR, Milne K, Truong PT et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011;13:R126.
9. Yamaguchi R, Tanaka M, Yano A et al. Tumorinfiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol 2012;43:1688-1694.
10. Schmidt M, Hellwig B, Hammad S et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin ? C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012;18:2695-2703.
11. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013;31:860-867.
12. Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959-2966.
13. Gu-Trantien C, Loi S, Garaud S et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013;123:2873-2892.
14. Disis ML, Stanton SE. Triple-negative breast cancer immune modulation as the new treatment paradigm. Am Soc Clin Oncol Educ Book 2015;e25-e30.
15. Salgado R, Denkert C, Demaria S et al. The evaluation of tumor-infiltrating lymphocytes (tumor-infiltrating lymphocytes) in breast cancer: recommendations by an International tumor-infiltrating lymphocytes Working Group 2014. Ann Oncol 2015;26:259-271.
16. von Minckwitz G, Schneeweiss A, Loibl S et al. Neoadjuvant carboplatin in patients with triplenegative and HER2-positive early breast cancer (Gepar-Sixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014;15:747-756.
17. Polley MY, Leung SC, McShane LM et al. An international Ki67 reproducibility study. J Natl Cancer Inst 2013;105:1897-1906.
18. Polley MY, Leung SC, Gao D et al. An international study to increase concordance in Ki67 scoring. Mod Pathol. 2015;28:778-786.
19. Perez EA, Press MF, Dueck AC et al. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 2013;138: 99-108.
20. Tung NM, Winer EP. Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer. J Clin Oncol 2015;33:969-971.